Fluoroquinolone Associated Disability

CompletedOBSERVATIONAL
Enrollment

239,306

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
BronchitisSinusitisUrinary Tract Infections
Interventions
DRUG

Fluoroquinolone (FQ)

Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.

DRUG

Azithromycin (AZ)

Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.

DRUG

Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination

Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.

Trial Locations (1)

08560

Janssen Investigative Site, Titusville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03535558 - Fluoroquinolone Associated Disability | Biotech Hunter | Biotech Hunter